Adebrelimab
- Generic Name
- Adebrelimab
- Drug Type
- Biotech
- CAS Number
- 2247114-85-6
- Unique Ingredient Identifier
- 1XBY50W1OX
- Background
Adebrelimab is under investigation in clinical trial NCT03711305 (Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-stage (ES) Small Cell Lung Cancer (SCLC)).
- Indication
用于与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。
Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial
- Conditions
- Small Cell Lung Cancer (SCLC)
- Interventions
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Tang-Du Hospital
- Target Recruit Count
- 104
- Registration Number
- NCT06485544
- Locations
- 🇨🇳
Tangdu Hospital Affiliated to the Fourth Military Medical University, Xi'an, Shannxi, China
A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer
- Conditions
- Small Cell Lung Cancer Limited Stage
- Interventions
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Jin Ying
- Target Recruit Count
- 38
- Registration Number
- NCT06483282
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Perioperative Treatment of Resectable Adenocarcinoma of Esophagogastric Junction by Immunotherapy (Adebrelimab) Combined With Chemotherapy (XELOX): a Prospective, Single-center, Feasibility Study
- Conditions
- Esophagogastric Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 26
- Registration Number
- NCT06482788
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-06-28
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Yunpeng Liu
- Target Recruit Count
- 38
- Registration Number
- NCT06480864
- Locations
- 🇨🇳
The First Hospital of China Medical University, Shenyang, China
A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma
- Conditions
- Esophageal Small Cell Carcinoma
- Interventions
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Zhangzhou Municipal Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06478264
Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 87
- Registration Number
- NCT06475326
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Adebrelimab + Apatinib in SCLC Maintenance Therapy
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Tang-Du Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06475209
- Locations
- 🇨🇳
Tangdu Hospital Affiliated to the Fourth Military Medical University, Xi'an, Shannxi, China
Neoadjuvant Adebrelimab + DOS in Locally Advanced Resectable Gastric Cancer
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Tang-Du Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT06475417
- Locations
- 🇨🇳
Tangdu Hospital Affiliated to the Fourth Military Medical University, Xi'an, Shannxi, China
Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer
- Conditions
- Advanced Breast CancerHormone-receptor-positive Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Interventions
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 32
- Registration Number
- NCT06470672
- Locations
- 🇨🇳
Fudan Cancer Hospital, Shanghai, Shanghai, China
To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer
- Conditions
- HR+/HER2- Breast CancerBreast Cancer
- Interventions
- Procedure: High Intensity Focused Ultrasoun（HIFU）
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-06-24
- Target Recruit Count
- 29
- Registration Number
- NCT06470633
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.